Joint Pain Injections Market Report 2025

This Joint Pain Injections market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The joint pain injections market size has grown rapidly in recent years. It will grow from $5.6 billion in 2024 to $6.17 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to increased aging population, arthritis prevalence, global health initiatives, healthcare digitalization, increasing awareness of chronic pain management.

The joint pain injections market size is expected to see rapid growth in the next few years. It will grow to $9.81 billion in 2029 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to expansion of telehealth services, personalized pain management, patient education and empowerment, sustainable healthcare practices, nutritional support. Major trends in the forecast period include regenerative medicine, personalized pain management, innovative injection materials, rehabilitation technologies, artificial intelligence ai-enhanced injections.

The increasing prevalence of arthritis and musculoskeletal disorders is expected to drive the growth of the joint pain injections market. Musculoskeletal disorders are the leading cause of disability globally, with low back pain identified as the most common cause of impairment in 160 countries. Patients often seek injections for pain relief and to manage inflammatory conditions. For example, in June 2023, the Australian Institute of Health and Welfare, a government agency in Australia, reported that rheumatoid arthritis accounted for 2% of the total disease burden and 16% of the overall burden of disease related to musculoskeletal conditions. In 2022, it resulted in 1,322 deaths, equating to 5.1 deaths per 100,000 people, which represented 0.7% of all deaths. Therefore, the rising prevalence of arthritis and musculoskeletal disorders is driving the joint pain injections market.

The rising incidence of chronic pain is anticipated to drive the growth of the joint pain injections market in the future. Chronic pain is characterized by persistent or long-lasting discomfort that continues for an extended duration, typically defined as lasting at least three to six months or beyond the expected healing time. Joint pain injections are commonly utilized to manage chronic pain, particularly when it is linked to musculoskeletal conditions such as osteoarthritis, rheumatoid arthritis, or other joint-related issues. For example, in September 2022, the World Health Organization (WHO) reported in its 2022 Highlights that there were 41 million deaths, accounting for 74% of all fatalities due to noncommunicable diseases (NCDs) or chronic diseases globally each year. Consequently, the increase in the incidence of chronic pain is propelling the growth of the joint pain injections market.

A prominent trend in the joint pain injections market is the focus on new product development. Major companies in this sector are actively engaged in innovating new products to meet consumer demand and enhance their market position. For instance, Contura International Ltd., a UK-based manufacturer of therapeutic hydrogels, introduced Arthrosamid in September 2021. Arthrosamid, an innovative hydrogel injection for knee osteoarthritis, utilizes non-biodegradable hydrogel technology, providing a potent, long-lasting, secure, and minimally intrusive treatment for knee osteoarthritis pain.

Leading companies in the joint pain injections market are concentrating on developing innovations such as single-injection formulations, which prioritize patient convenience. A single-injection formulation is a type of drug delivery system designed to deliver a specific dose of medication in a single injection, offering sustained therapeutic effects over an extended period without the need for multiple doses. For example, in July 2024, LG Chem Ltd., a chemicals company based in South Korea, introduced Synovian, a new treatment for knee osteoarthritis in China that features a convenient single-injection formulation, making it the first of its kind in the country. The product aims to capture a significant market estimated at around KRW 200 billion (approximately USD 150 million). Developed using proprietary technology, it demonstrates innovation in meeting patient needs, focusing on providing effective relief with minimal administration effort.

In November 2022, Biocon Biologics Limited, a pharmaceutical company based in India, acquired the biosimilars business from Viatris Inc. for $3.33 billion. This acquisition enables Biocon to utilize Viatris' extensive experience and established presence in the global market, improving access to critical therapies for patients around the world. This strategic move is anticipated to enhance its biosimilars portfolio, including Adalimumab BS for subcutaneous injection, which is indicated for immune-related diseases like rheumatoid arthritis. Viatris Inc. is a healthcare company based in the US that offers joint pain medications.

Major companies operating in the joint pain injections market include Seikagaku Corporation, Flexion Therapeutics Inc., Zimmer Biomet Holdings Inc., Sanofi S.A., Anika Therapeutics Inc., Abbvie Inc., Bioventus Inc., Eli Lilly and Company, Ferring Pharmaceuticals Inc., Pfizer Inc., Teva Pharmaceutical Industries Limited, Johnson & Johnson Services Ltd., Merck & Co. Inc., GlaxoSmithKline plc, Novartis AG, AstraZeneca plc, Roche Holding AG, Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Takeda Pharmaceutical Company Limited, Bayer AG, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen SA, Mallinckrodt Pharmaceuticals Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., Zydus Lifesciences Limited.

North America was the largest region in the joint pain injections market in 2024. The regions covered in the joint pain injections market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the joint pain injections market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

Joint pain injections serve to reduce inflammation and discomfort, typically administered directly into the joint to alleviate pain. Joint pain is a common occurrence, particularly among the elderly or individuals with pre-existing medical conditions or disorders. Conditions such as arthritis, characterized by pain and inflammation, often contribute to joint pain. Joint pain injections offer a non-surgical approach to quickly relieve joint pain and inflammation.

The primary types of injections for joint pain include steroid joint injections, hyaluronic acid injections, platelet-rich plasma (PRP) injections, placental tissue matrix (PTM) injections, and various others. Steroid joint injections, also known as corticosteroid injections, are anti-inflammatory medications used to treat joint pain. They are particularly effective in reducing inflammation in individuals with conditions like rheumatoid arthritis and other forms of inflammatory arthritis. Joint pain injections are applied to various types of joints, including the hip joint, knee and ankle joints, shoulder and elbow joints, facet joints of the spine, and others. These injections are commonly distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The joint pain injections market research report is one of a series of new reports that provides joint pain injections market statistics, including joint pain injections industry global market size, regional shares, competitors with a joint pain injections market share, detailed joint pain injections market segments, market trends and opportunities, and any further data you may need to thrive in the joint pain injections industry. This joint pain injections market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The joint pain injections market consists of sales of epidural steroid injections, facet joint injections, viscosupplementation injections, corticosteroid injections and hyaluronic acid injections. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.